Sugi Predict

Sugi Predict / Compounds / SCHEMBL707964

SCHEMBL707964

SCHEMBL707964

O=C1COc2ccc(S(=O)(=O)Cl)cc2N1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 7/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ MMP12 P39900 1/20 0.58
▸ KMT2A Q03164 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ LMNA P02545 1/20 0.55
▸ PARP1 P09874 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.52
▸ MAPT P10636 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.51
▸ NR3C2 P08235 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3175004 0.88 LMNA (0.50) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL29893671 0.84 PKM (0.59) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL30197829 0.84 SMN1; SMN2 (0.62) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL1744758 0.84 PKM (0.59) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL707711 0.84 SMN1; SMN2 (0.62) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL1970405 0.84 PKM (0.59) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL706059 0.82 PARP1 (0.62) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL10154038 0.81 SMN1; SMN2 (0.69) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL20364687 0.81 SMN1; SMN2 (0.58) PKMSMN1; SMN2MMP12KMT2AMEN1
SCHEMBL2898736 0.81 PKM (0.59) PKMSMN1; SMN2MMP12KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4721737-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES Scinnohub Pharmaceutical Co., Ltd. (CN) 2026-04-08 — — EP disclosed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed
WO-2025100970-A1 TNAP INHIBITORY COMPOUND AND USE THEREOF 주식회사 레드엔비아 2025-05-15 — — WO disclosed
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 — — US disclosed
CN-119504729-A Preparation method of Beclin1-ATG14L interaction inhibitor 烟台皓元生物医药科技有限公司 2025-02-25 — — CN disclosed
WO-2024245143-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES 赛诺哈勃药业（成都）有限公司 2024-12-05 — — WO disclosed
EP-4455136-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE Scinnohub Pharmaceutical Co., Ltd. (CN) 2024-10-30 — — EP disclosed
CN-118510768-A Diazasulfinyl structure-containing compounds and their use in medicine 赛诺哈勃药业（成都）有限公司 2024-08-16 — — CN disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 — — WO disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 — — WO disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 — — WO disclosed
WO-2007098418-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2007-08-30 — — WO disclosed
WO-2007098418-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2007-08-30 — — WO disclosed
WO-2006134378-A1 COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2006-12-21 — — WO disclosed
US-20040267010-A1 Sulfonamide compounds, their preparation and use SMITHKLINE BEECHAM P.L.C. (GB) 2004-12-30 — — US disclosed
EP-1355902-A1 SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE SMITHKLINE BEECHAM PLC (GB) 2003-10-29 — — EP disclosed
WO-2002062788-A1 SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE SMITHKLINE BEECHAM P.L.C. (GB) 2002-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE BCL9, USP9X, BCL9L PKM 266/4885SMN1; SMN2 1443/4885MMP12 3292/4885
US-20040267010-A1 Sulfonamide compounds, their preparation and use HTR7, HTR6, SIGMAR1 PKM 3083/4885SMN1; SMN2 1289/4885MMP12 4513/4885
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 PKM 1182/4885SMN1; SMN2 2854/4885MMP12 2960/4885
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 PKM 3856/4885SMN1; SMN2 3395/4885MMP12 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.